@article{2ae68296c37849ddbd64faf9df49ef61,
title = "Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial",
keywords = "clinical trial, diabetes complications, diabetic neuropathy, empagliflozin, linagliptin, SGLT2 inhibitor",
author = "Laursen, {Jens Christian} and {Rotbain Curovic}, Viktor and Kroonen, {Marjolein Y.A.M.} and Niels Jongs and Zobel, {Emilie H.} and Hansen, {Tine W.} and Marie Frimodt-M{\o}ller and Laverman, {Gozewijn D.} and Adriaan Kooy and Frederik Persson and Heerspink, {Hiddo J.L.} and Hansen, {Christian Stevns} and Peter Rossing",
note = "Funding Information: The authors thank all participants and clinical trial staff for participation in this study. The study was funded by Boehringer Ingelheim and a grant from the Novo Nordisk Foundation (NNF14OC0013659 PROTON Personalizing Treatment of Diabetic Nephropathy). The funders were not involved in the design, execution, analysis, interpretation of the data nor in the writing of the manuscript. ",
year = "2023",
doi = "10.1111/dom.15180",
language = "English",
volume = "25",
pages = "3064--3067",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "10",
}